Navigation
banner

All posts by GTCbio

2017

Enzymes in Drug Discovery Summit

GTCbio | November 7th, 2017

Enzymes have historically been considered attractive drug targets for therapeutics because of their specificity and susceptibility to drug modulation. More than 250 genes coding for enzymes, have been identified as FDA-approved drug targets and this further highlights the continued importance of investigating enzyme targets. Therefore, with the rise in demand for effective therapeutic agents, the…read more

Immunology and Immunotherapy

GTCbio | October 24th, 2017

Immunotherapy involves treatment of diseases by induction, enhancement, or suppression of an immune response. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immune cell activation and differentiation occurs concurrently with metabolic reprogramming. This ensures that activated cells generate…read more

Next Generation Sequencing

GTCbio | September 8th, 2017

Nucleotide sequencing is the method used for determining the precise order of nucleotides within a DNA/RNA molecule. The identification of complete gene and the complete genome of Bacteriophage MS2 in 1972 and 1976 respectively; and the invention of the first method for DNA sequencing involving a location-specific primer extension strategy in 1970 were the major…read more

GTCbio is excited to partner with Midwest Stem Cell Therapy Center at Kansas University Medical Center for 5th Annual Midwest Conference on Cell Therapy and Regenerative Medicine

GTCbio | August 30th, 2017

The Midwest Stem Cell Therapy Center (MSCTC) was established in 2013 to serve as a regional hub to facilitate stem cell research and clinical development. Since its inception, MSCTC has made significant progress in the adult stem cell field. A key goal of MSCTC is to educate regional and national stem cell enthusiasts about the…read more

Finalists Announced for the New Company/Technology Pitch Competition at the CNS Diseases Summit

GTCbio | August 25th, 2017

GTCbio is excited to announce the finalists for the inaugural new company/technology pitch competition at the CNS Diseases summit scheduled for Sep 11-12, 2017 in Boston. The following companies will compete for the “Most Promising New Technology” award and $5000 monetary prize. Orion BioScience – developing innovative therapies to cure autoimmune diseases using a soluble…read more

CRISPR & Genome Engineering

GTCbio | August 16th, 2017

CRISPR (Clusters of Regularly Interspaced Short Palindromic Repeats) is a specialized region of DNA comprised of two distinct characteristics including presence of nucleotide repeats and spacers. The term CRISPR is used interchangeably with CRISPR-Cas9. Cas9 (CRISPR-associated) is a protein that acts like molecular scissors cutting strands of DNA. It is basically a system inherent in…read more

Experimental Therapeutics & Approaches in Alzheimer’s Disease & Related Dementias

GTCbio | August 3rd, 2017

Alzheimer’s disease (AD), is a chronic neurodegenerative disease that usually starts slowly and worsens over time and although often appearing in people over 65 years of age, it is not just a disease of old age. It is estimated that approximately 200,000 Americans under the age of 65 have “early-onset” AD. It is believed that…read more

Development of Novel Technologies for Cell and Gene Therapy

GTCbio | July 26th, 2017

Gene therapy is the use of genetic material (usually DNA) to manipulate a patient’s cells as a means to treat diseases, whereas cell therapy is the infusion or transplantation of whole cells into a patient for the treatment of an inherited or acquired disease, both are overlapping fields of biomedical research. In 1990, the first…read more

Advances in Parkinson’s Disease Research and Therapeutics

GTCbio | July 20th, 2017

Parkinson’s disease, the second-most common neurodegenerative disorder affecting 2–3% of the population ≥65 years of age has seen significant developments in past few years in terms of diagnosis and therapeutics. The collaboration between the European Human Brain Project and the U.S. Brain Initiative may result in a milestone for brain related diseases just as the…read more

Prominent Scientists will discuss Evolution of Cell and Gene Therapy

GTCbio | July 11th, 2017

Cell and gene therapy are overlapping fields of biomedical research that address the repair of the direct cause of genetic diseases in the cellular population or DNA, respectively. Cell therapy can be defined as a therapy in which cells or cellular material are injected into a patient. The origins of cell therapy can perhaps be traced to…read more

Public & Private Partnerships in Support of Global Health

GTCbio | May 11th, 2017

Reconciling the gap in global health issues happens when institutions recognize that they cannot work alone. Partnerships with domestic and international organizations to share global health objectives will improve collective knowledge and data and therefore, aid in analyzing worldwide trends. The goal of these partnerships is to promote research and development, drive new policies, establish…read more

Regulatory Considerations to Bring Antibody Therapies to Market

GTCbio | May 9th, 2017

As novel Antibody and Protein-based therapies are showing clinical promise in human trials, the field will require new measures of coordination with regulatory agencies to ensure these new therapeutic approaches are brought safely and in a timely fashion to market. Although, there is high interest in expediting Antibody and Protein-based therapies, the regulatory approval is…read more

Where do we stand with cell therapy in diabetes?

GTCbio | February 24th, 2017

Diabetes results from the dysfunction and/or destruction of the insulin producing beta cells in the pancreatic islet. Replacement of beta cells by using progenitor or differentiated stem cells is a promising strategy to treat diabetes.